Catalyst

Slingshot members are tracking this event:

SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BIIB

100%

Additional Information

Additional Relevant Details The MAA is based on a robust preclinical and clinical data package comparing SB5 with Humira. The clinical data include results from two head-to-head studies – a Phase I study in healthy volunteers that demonstrated pharmacokinetic bioequivalence to Humira and a Phase III, randomized, double-blind, multicenter study, in which SB5 demonstrated comparable efficacy, safety, and immunogenicity to Humira in patients with RA. The primary endpoint of the Phase III study, the ACR20 score response at Week 24, was met, demonstrating equivalent efficacy to Humira. Secondary endpoints demonstrated that SB5 has a comparable safety and immunogenicity profile to Humira.

http://www.businessw...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sb5, Humira, Biosimilar, Ema, Benepali, Etanercept, Remicade, Crohn's Disease, Ankylosing Spondylitis, Plaque Psoriasis